AstraZeneca invests $445m in expanded Texas manufacturing facility

The project will support the global manufacture of Lokelma which is use to treat hyperkalaemia – an elevated level of potassium in the blood. When severe the condition can cause palpitations, muscle pain or weakness or numbness.

The latest move is part of AstraZeneca's strategy, announced in July, to invest $50 billion in US R & D and manufacturing over the next five years.

The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world. It follows groundbreaking last week at AstraZeneca’s manufacturing facility in Albemarle County, Virginia.

Jim Fox, Senior Vice President, Americas Supply Operations, AstraZeneca, said: “Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce over the past 10 years. The expansion underscores our commitment to patients and support for Texas’ long-term vision for scientific growth and innovation.”

AstraZeneca’s Coppell facility is the sole global manufacturing facility of Lokelma to serve more than 50 countries. The facility employs more than 250 people.

Through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities and administrative space.

The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The company’s US workforce tops more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.